Effectiveness of Ethanolamine Oleate as a Pleural Sclerosing Agent in Rabbits

Teixeira, Lisete R.; Vargas, Francisco Suso; Carmo, Alipio O.; Silva, Lea M.M.F.; Marchi, Evaldo; Light, Richard W.

doi:10.1159/000029281

Cited by 5 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, after completion of the treatment schedule, in the long‐term follow up, a statistically significant reduction was observed ( P < 0.05) in the mean ASS and volume of TBE (Tables and ). The local inflammatory properties of the EO injection may explain these results . EO injection was well tolerated by all of the patients with minor side‐effects.…”

Section: Discussionmentioning

confidence: 87%

“…The local inflammatory properties of the EO injection may explain these results. [3][4][5][6][7] EO injection was well tolerated by all of the patients with minor side-effects. These results suggest that EO injection is a safe and effective agent in the treatment of selected IA patients.…”

Section: Discussionmentioning

confidence: 99%

“…EO injection has been used for the treatment of bleeding esophageal varices, varicose veins in the legs, and reactive vascular lesions . The responsible component for the induced inflammation is oleic acid .…”

Section: Introductionmentioning

confidence: 99%

“…EO injection has been used for the treatment of bleeding esophageal varices, varicose veins in the legs, and reactive vascular lesions. [3][4][5] The responsible component for the induced inflammation is oleic acid. 3,6 Our hypothesis is that EO injection in LES causes loss of excitatory neurons in the myenteric plexus by inducing inflammation, damage, and fibrosis of the tissue.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ethanolamine oleate as a novel therapy is effective in resistant idiopathic achalasia

et al. 2013

View full text Add to dashboard Cite

Idiopathic achalasia (IA) is a primary motor disorder of the esophagus. Recently, ethanolamine oleate (EO) has been introduced as a novel therapy in IA. We investigate the long-term efficacy of EO injection in the selected IA patients. Two hundred twenty patients with IA were evaluated prospectively. Thirty-one patients who were resistant to or poor candidate of pneumatic balloon dilation and/or cardiomyotomy were enrolled in this study. EO was injected into the lower esophageal sphincter three times at 2-week intervals. Patients were evaluated with the achalasia symptom score (ASS), timed barium esophagogram, and manometry before and after the injections. A good response was defined as a greater than 50% reduction from baseline in the ASS, height and/or volume of barium in TBE, and absence of severe dysphagia or regurgitation at 1.5 months after the last injection. Relapse was defined as two or more points increase in dysphagia score after an initial good response. The mean age of patients was 49.32 ± 19.3 years. Twenty-nine patients had a good response and two had a poor response. The mean ASS decreased from 12.48 (±2.06) to 4.50 (±2.96) (P = 0.0001), and the mean volume of barium decreased from 115.35 (±93.40) to 45.50 (±60.86) mL at 1.5 months after the last injection (P = 0.0001).The mean lower esophageal sphincter pressure was 30.47 ± 13.95 before the treatment and decreased to 14.30 ± 11.89 at 1.5 months after the treatment. (P = 0.0001). The mean duration of follow up was 30.16 ± 11.3 (18-68) months. Twelve patients in whom symptoms relapsed were treated effectively with reinjection. In some patients, minor complications (chest pain and erosion in the distal esophagus) occurred. This study indicates that EO has a long-term effect and can be considered for use in the selected IA patients.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ethanolamine oleate as a novel therapy is effective in resistant idiopathic achalasia

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Several substances have been studied both clinically and experimentally, such as ethanolamine oleate, diazepam, erythromycin, macrolides, quinolones, povidone-iodine, and quinacrine, among others [4–7]. All of these studies intend to find an agent with the following characteristics: (1) efficient, (2) widely available, (3) of low cost, and (4) of few side effects.…”

Section: Introductionmentioning

confidence: 99%

Pleurodesis Induction in Rats by Copaiba (Copaifera multijugaHayne) Oil

Westphal

Canzian

Pieri

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

This study aims to assess and compare copaiba oleoresin of Copaifera multijuga and 0.5% silver nitrate for the induction of pleurodesis in an experimental model. Ninety-six male Wistar rats were divided into three groups: control (0.9% saline solution), copaiba (copaiba oil), and silver nitrate (0.5% silver nitrate). The substances were injected into the right pleural cavity and the alterations were observed macroscopically and microscopically at 24, 48, 72, and 504 h. The value of macroscopic alterations grade and acute inflammatory reaction grade means was higher in the 24 h copaiba group in relation to silver nitrate. Fibrosis and neovascularization means in the visceral pleura were higher in 504 h copaiba group in relation to the silver nitrate group. The grade of the alveolar edema mean was higher in the silver nitrate group in relation to the copaiba group, in which this alteration was not observed. The presence of bronchopneumonia was higher in the 24 h silver nitrate group (n = 4) in relation to the copaiba group (n = 0). In conclusion, both groups promoted pleurodesis, with better results in copaiba group and the silver nitrate group presented greater aggression to the pulmonary parenchyma.

show abstract